Development of a substance based on the principle of phage therapy and advanced biocompatible materials to suppress staphylococcal infections of the skin of dogs and cats
Project number: FW12010450
Main beneficiary: Pro-Charitu Ltd.
Other beneficiaries: Biology Centre CAS
Principal investigator for BC: prof. RNDr. Karel Petrzik, CSc.
Project duration: 01.01.2025 - 31.12.2027
The aim of the project:
Even veterinary practice faces an increasing incidence of hard-to-treat bacterial infections. In the clinical practice of our partner, more than 55% of Staphylococcus pseudintermedius isolates from dogs and cats showed resistance to more than five antibiotics. The spread of antibiotic resistance cannot be easily prevented; however, it is possible to reduce the selective pressure for its emergence by limiting inappropriate or ineffective use of antimicrobials and by combining their effects with other approaches.
An alternative could be the use of lytic bacteriophages, which are a natural part of the biosphere and regulate bacterial populations within it.
Our task in the project is to identify, isolate, and characterize lytic phages specific to strains of S. pseudintermedius, which causes skin diseases (pyoderma) in dogs and cats, as well as urinary tract infections, otitis media, chronic rhinitis, and respiratory diseases.
The aim of the project is to prepare a mixture of several different bacteriophages and, in cooperation with CEITEC BUT Brno, test their effectiveness in the treatment of pyoderma using patented hydrogel dressings and foams.
Occurrence of resistant S. pseudintermedius in LMS practice in period 1.1.2023 – 30.6. 2024
Inoculation of two found phages on a culture of S. pseudintermedius
Genome of the new bacteriophage Staphylococcus BoBr and predicted functions of its genes
Bacteriophage search team
This project has been financed with the state support of the Technology Agency of the Czech Republic and the Ministry of the Environment of the Czech Republic within the Environment for Life Programme .
